Venture Capital

What's New

1.9 billion

Since 2007, we have represented investors and portfolio companies in financing transactions totaling nearly $1.9 billion.

Overview

Honigman's Venture Capital Practice Group represents clients involved in all aspects of the financing, operation and sale of technology companies both in the United States and other parts of the world. Our investor clients include institutional venture capital funds, strategic investors, venture capital fund-of-funds and angel investors. Our technology-based clients cover a broad variety of industries from software to drug therapies.  We represent both investors and their portfolio companies throughout the life span of growth, ranging from seed capital to growth equity for later-stage enterprises.  Our counterparts in these transactions are frequently coastal law firms located in traditional technology areas, including Silicon Valley and Boston.

In representing investors, we have formed both venture capital funds and fund-of-funds devoted to investing in venture capital funds. Our attorneys also assist fund investors in making portfolio company investments and advising in the sale of venture-backed companies.

Honigman's Venture Capital Practice Group has a long-history of forming new companies and preparing them for investment and eventual sale or initial public offering.  We help companies manage and mitigate risk involved in growth, taking venture capital, borrowing venture debt, and protecting and licensing technology from commercial and academic licensors.  In doing so, we bring to bear the firm’s broad experience in corporate governance, financing, deal structuring, tax, intellectual property, employment  and benefit matters, product manufacture and distribution, and mergers and acquisitions.  We have also represented a variety of clients in corporate restructuring transactions, including conversions from and to limited liability companies to take best advantage of tax and operational considerations.

Since 2007, we have represented investors and portfolio companies in financing transactions totaling nearly $1.9 billion, and have represented more than 30 technology-based companies in sales to strategic and financial buyers for a total sales price of more than $300 million.

Representative Matters

Representative Venture Capital and Technology Transactions
  • Represented a variety of companies and investors in financing transactions for medical device, information technology, clean-energy, advanced materials and manufacturing, diagnostics and drug therapy companies
  • Advised numerous technology-based companies in licensing transactions
  • Represented an Internet satisfaction information technology company in receiving investments from off-shore institutional venture capital investors and multiple venture debt providers
  • Advised a diagnostics company in joint marketing and joint development arrangements with a large pharmaceutical company
  • Represented a medical device company in its sale to a multinational corporation
  • Represented a multinational corporation in many of its strategic venture investing activities
  • Advised venture investors in investments in Canada, Israel, Germany, Brazil and India
  • Advised a research company in its sale of a major division to a publicly held company
  • Assisted a battery technology company in its sale to a venture-backed battery provider
  • Advised on the acquisition of an enterprise resource planning information technology company on behalf of a venture-backed company in the same technology space
  • Negotiated a cross-border joint technology development agreement with a multinational company on behalf of a medical device company
  • Provided advice for an early stage investment in a company specializing in the delivery of web-based educational software by a Michigan-based venture fund
  • Represented a stat positioning device company in its sale to a publicly held company

Representative Clients

Venture Capital Funds
Agency Business Solutions LLC O2 Investment Partners
Arboretum Ventures Open Prairie Ventures Fund III, L.P.
Camelot Ventures LLC Plymouth Venture Partners
Detroit Venture Partners Renaissance Venture Capital Fund L.P.
Early Stage Partners Renaissance Venture Capital Fund II, L.P.
Huron River Ventures RPM Ventures
Michigan Angel Fund Venture Investors
Michigan Growth Capital Partners Venture Michigan Fund
Novus Biotechnology Fund 1, L.P.  
     
Company Clients
Ablative Solutions, Inc.  Innovative Cardiovascular Solutions, LLC 
Angel Medical Systems  Metabolic Solutions Development Company 
Armune Biosciences, Inc.  Molecular Imaging, Inc.
Aseko, Inc.  Northstar Imaging Solutions, LLC 
AvaSure Holdings, Inc.  ONL Therapeutics, LLC 
CompTherapeutics, LLC  ProNAi Therapeutics, Inc. 
eNEURA Therapeutics, LLC QXMedical, LLC 
ForeSee Results, Inc.  RealBio Technology, Inc. 
Handstand Innovations, LLC  Svelte Medical Systems, Inc. 
HellaStorm, Inc.  Swift Biosciences, Inc. 
HistoSonics, Inc.  Vestaron Corporation f-k-a Venomix, Inc.

News & Resources

Events

Publications